Clinical Oncology
Volume 19, Issue 2 , Pages 150-153 , March 2007

13-cis-Retinoic Acid in Combination with Gemcitabine in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer — Report of a Pilot Phase II Study

  • A. Michael

      Affiliations

    • Oncology Department, St George's Hospital, St James' Wing, Blackshaw Road, London SW17 0QT, UK
    • Corresponding Author InformationAuthor for correspondence: A. Michael, Oncology Department, St George's Hospital, St James' Wing, Blackshaw Road, London SW17 0QT, UK. Tel: +44-1372721759; Fax: +44-2087253972.
    • ,
  • M. Hill

      Affiliations

    • Maidstone General Hospital, Hermitage Lane, Maidstone, Kent ME16 9QQ, UK
    • ,
  • A. Maraveyas

      Affiliations

    • Princess Royal Hospital, Salthouse Road, Hull HU8 9HE, UK
    • ,
  • A. Dalgleish

      Affiliations

    • Oncology Department, St George's Hospital, St James' Wing, Blackshaw Road, London SW17 0QT, UK
    • ,
  • F. Lofts

      Affiliations

    • Oncology Department, St George's Hospital, St James' Wing, Blackshaw Road, London SW17 0QT, UK

Received 15 August 2006 ,Revised 23 October 2006 ,Accepted 8 November 2006.

References 

  1. Toms JR. CancerStats monograph. UK: Cancer Research; 2004;
  2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413
  3. Bollag W, Majewski S, Jablonska S. Cancer combination chemotherapy with retinoids: experimental rationale. Leukemia. 1994;8:1453–1457
  4. Lippman SM, Heyman RA, Kurie JM, Benner SE, Hong WK. Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem Suppl. 1995;22:1–10
  5. Lotan R. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res. 1996;16:2415–2419
  6. Nagy L, Thomazy VA, Heyman RA, Davies PJ. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ. 1998;5:11–19
  7. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889–895
  8. Heyman RA, Mangelsdorf DJ, Dyck JA, et al. 9-cis Retinoic acid is a high affinity ligand for the retinoid X receptor. Cell. 1992;68:397–406
  9. Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW. Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer. 2002;87:555–561
  10. Balasubramanian S, Chandraratna RA, Eckert RL. Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid. Carcinogenesis. 2004;25:1377–1385
  11. El-Metwally TH, Hussein MR, Pour PM, Kuszynski CA, Adrian TE. High concentrations of retinoids induce differentiation and late apoptosis in pancreatic cancer cells in vitro. Cancer Biol Ther. 2005;4:602–611
  12. El-Metwally TH, Hussein MR, Pour PM, Kuszynski CA, Adrian TE. Natural retinoids inhibit proliferation and induce apoptosis in pancreatic cancer cells previously reported to be retinoid resistant. Cancer Biol Ther. 2005;4:475–483
  13. Balasubramanian S, Chandraratna RA, Eckert RL. A novel retinoid-related molecule inhibits pancreatic cancer cell proliferation by a retinoid receptor independent mechanism via suppression of cell cycle regulatory protein function and induction of caspase-associated apoptosis. Oncogene. 2005;24:4257–4270
  14. Pettersson F, Colston KW, Dalgleish AG. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas. 2001;23:273–279
  15. Brembeck FH, Schoppmeyer K, Leupold U, et al. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer. 1998;83:2317–2323
  16. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1–10
  17. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181–193
  18. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986;315:1501–1505
  19. Grunwald F, Pakos E, Bender H, et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med. 1998;39:1555–1558
  20. Kelly WK, Osman I, Reuter VE, et al. The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer. Clin Cancer Res. 2000;6:838–846
  21. Somos S, Farkas B. Immunomodulatory treatment with low-dose interferon-alpha and oral retinoic acid in lymphangioma-like Kaposi's sarcoma. Anticancer Res. 2000;20:541–545
  22. Lawrence JA, Adamson PC, Caruso R, et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol. 2001;19:2754–2763
  23. Miller WH, Reyno LM, Loewen GR, et al. A phase I–II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study. Ann Oncol. 2000;11:1387–1389
  24. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:2972–2980
  25. Kurie JM, Lee JS, Griffin T, et al. Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin Cancer Res. 1996;2:287–293
  26. Kraemer KH, DiGiovanna JJ, Peck GL. Chemoprevention of skin cancer in xeroderma pigmentosum. J Dermatol. 1992;19:715–718
  27. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med. 1988;318:1633–1637
  28. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165–1173
  29. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001;93:605–618
  30. Park TK, Lee JP, Kim SN, Choi SM, Kudelka AP, Kavanagh JJ. Interferon-alpha 2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur J Gynaecol Oncol. 1998;19:35–38

PII: S0936-6555(06)00422-5

doi: 10.1016/j.clon.2006.11.008

Clinical Oncology
Volume 19, Issue 2 , Pages 150-153 , March 2007

Article Tools